Also, we provide evidence that Drp1 downregulation contributes to the reduced proliferation and motility of PD‐1pos tumor‐infiltrating T cells, and, as a consequence, we identify Drp1 as a possible target for future therapeutic approaches aiming at restoring antitumor response in PD‐1pos exhausted CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.